Damora Therapeutics, Inc. Financials

DMRA

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 7 available years

Income Statement	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021 ~5.5:1 split
General & Administrative	$10	$10	$13	$13	$14
Research & Development	$27	$6	$24	$48	$38
Total Operating Expenses	$211	$22	$40	$61	$52
Operating Income	-$211	-$22	-$40	-$61	-$52
Other Non-Operating Income (Expense)	$1	$1	$1	-$1	$1
EBT (Earnings Before Tax)	-$210	-$21	-$38	-$62	-$52
Income Tax Expense	$0	$0	$0	$0	$0
Net Income
Net Income	-$210	-$21	-$38	-$62	-$52
EPS (Basic)	$3.98	-$18.53	-$36.08	-$60.75	-$51.25
EPS (Diluted)	$3.98	-$18.53	-$36.08	-$60.75	-$51.25
Weighted Avg Shares (Basic)	1.4M	1.2M	26.6M	25.4M	25.3M
Weighted Avg Shares (Diluted)	1.4M	1.2M	26.6M	25.4M	25.3M
Shares Outstanding	1.4M	1.2M	1.1M	1.0M	1.0M
Dividends Per Share	$0.00	$0.00	–	–	$0.00

Damora Therapeutics (DMRA) financials: revenue, profit and margins

Damora Therapeutics (DMRA) generated about n/a in revenue and -$263 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Damora Therapeutics profitable?+

Damora Therapeutics reported about -$263 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on DMRA: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DMRA

CompareIntrinsic value

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

SCYXScynexis, Inc.

$3.84-2.54%40

HROWHarrow Inc.

$28.75+0.74%46

HRTXHeron Therapeutics Inc.

$0.30+7.14%36

RCKTRocket Pharmaceuticals Inc.

$2.61+3.98%10

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

MRKMerck & Co., Inc.

$150.36+3.93%41

Held by ETFs

DMRA is in 23 US ETFs. The largest of them, with DMRA's weight in each:

Spot a number that looks wrong? Check it in DMRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DMRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.